european

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

LEATHERHEAD, England, July 3, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has…

14 hours ago

FAIR PLAY MENARINI INTERNATIONAL AWARD, LUIS FIGO JOINS THE GREAT SPORTS STARS ACKNOWLEDGED IN 2025

FLORENCE, Italy, July 1, 2025 /PRNewswire/ -- Surprises never end when it comes to the Fair Play Menarini International Award:…

2 days ago

Bybit Launches Bybit.eu, a Fully MiCAR-Compliant Platform for Europe’s Crypto Users

VIENNA, Austria, July 2, 2025 /PRNewswire/ --  Bybit, the world's second-largest cryptocurrency exchange by trading volume, today announced the official…

2 days ago

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals…

2 weeks ago

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb…

2 weeks ago

New Kia App provides European drivers with a unified digital experience

Europe-wide rollout of the all-in-one Kia App starts in MayKia Connect, Kia Charge, MyKia, Kia Warranty Book and Kia Owner’s…

2 weeks ago

Gorenje continues long-term partnership with EHF Champions League

Monday 16 June, 2025 Appliance brand Gorenje is prolonging its involvement in the premium club competitions of the European Handball…

2 weeks ago

AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…

3 weeks ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

3 weeks ago

GENESIS ANNOUNCES MAJOR EUROPEAN MARKET EXPANSION AT LE MANS

Genesis Motor Europe will expand operations into four new marketsThe Korean car brand will launch in France, Italy, Spain and…

3 weeks ago